Background: Certolizumab pegol is a pegylated fab fragment of a humanized TNF inhibitor monoclonal antibody. It is approved by NICE for use in RA where patients have tried two DMARDS including MTX, have a DAS28 score of greater than 5.1 on two occasions 4 weeks apart, and the manufacturer supplies the first 12 weeks free of charge. We aimed to study the use and effectiveness of certolizumab pegol in the treatment of RA. Methods: We performed a retrospective review of consecutive patients commenced on certolizumab pegol for RA at Imperial College Healthcare NHS Trust (St Mary's, Charing Cross and Hammersmith hospitals). We identified patients in the biologics registry from first use in April 2010 until study end in April 2013. Information was collected using patient case notes and the laboratory results system. Results: 31 patients were commenced on certolizumab pegol for RA. 25 of these were female and 6 were male. Mean age was 60.22 years AE 13.88 (S.D.). Disease duration was 1-5 years in 29%, 6-10 years in 19.4%, and 32.3% more than 10 years. Median baseline DAS28 score was 6.3 [mean (S.D.) 6.14 ( Background: AZA, used to treat a variety of medical conditions, is metabolized by an enzyme called thiopurine methyltransferase (TPMT) . Approximately 11% of the population have reduced levels of TPMT and up to 0.6% are deficient. TPMT deficiency may lead to delayed haematotoxicity in patients prescribed AZA. The British Societies for Rheumatology and Dermatology recommend that TPMT levels are measured prior to AZA treatment but we are aware that practice varies widely. We sought to understand the utility of TPMT testing in patients with rheumatic diseases. Specific objectives were to describe the frequency of testing, actions taken where abnormalities of TPMT occur and to report frequency and nature of drug toxicity in patients with different levels of TPMT. Methods: TPMT requests made by rheumatologists between 1 January 2011 and 31 December 2012 were identified from a log kept in the department of Biochemistry. Clinical data including demographics, primary diagnoses, dates and results of TPMT tests, date of prescription, drug doses and adverse reactions were extracted from electronic records. Results: Of 550 test requests 62 (11.3%) were made by rheumatologists and of these 14/62 (22.6%) did not commence AZA during follow-up. Patients had a mean age of 55.8 years (range 20-89) and 82% were female. Primary diagnoses included: SLE and related conditions (24.2%); RA (35.5%); seronegative arthritis (14.5%) and cranial arteritis and PMR (11.3%). No patient was TPMT deficient, 7 (11.3%) patients had a low level (20-67) and 55 (88.7%) normal levels. Of 48 patients starting AZA 20 (32.3%) started before TPMT results were available. Starting doses (25 to 50 mg per day) were similar in patients with low or normal levels of TPMT. Adverse effects occurred in 31/48 (64.6%) patients: gastrointestinal effects occurred in 19 (39.6%) patients and haematological problems in 5 (10.4%) patients (all of whom had a normal TPMT level). Conclusion: TPMT requests from rheumatology form a small proportion of all requests to a hospital biochemistry department. A significant proportion of patients do not start AZA and frequently the drug is started without knowledge of the TPMT result. Presumed haematological toxicity is infrequent and not related to baseline TPMT levels in this small cohort. Gastrointestinal toxicity, not related to TPMT levels, is very common and frequently leads to drug cessation. 
